

## Aurealis Pharma To Attend The Swiss Biotech Day in Basel, May 3<sup>rd</sup> 2018

Basel Switzerland, Kuopio Finland – April 26<sup>th</sup> 2018.

Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CEO Juha Yrjänheikki and CMO Dirk Weber will attend and discuss the company's progress at the Swiss Biotech Day in Basel on May 3<sup>rd</sup> 2018.

The Swiss Biotech Day has long become the standard annual get-together of the Swiss bio-pharmaceutical industry. It includes company presentations, partnering, exhibition, lectures and General Assembly of Swiss Biotech Association.

"AUP-16 hits all the key points for the patients with chronic wounds – anti-inflammation, angiogenesis induction and granulation tissue promotion. For that reason, the leading wound care clinical opinion leaders support us and believe that this therapy can make a difference in this devastating disease" stated CMO Dirk Weber, MD, PhD.

"We are pleased to attend and update the investors, pharma and biotech community of our diabetic foot and vascular leg ulcer product AUP-16, which is scheduled to start our first-in-human study in patients this year. AUP-16 is the first ever three-in-one multitherapy option for chronic wound sufferers" said CEO Yrjänheikki.

AUP-16 is the lead product from Aurealis Pharma "combination biologics in one product" technology platform. It is a genetically engineered *Lactococcus lactis*, a non-pathogenic, probiotic bacteria, expressing human basic fibroblast growth factor (FGF2, bFGF), interleukin-4 (IL-4) and macrophage colony stimulating factor (CSF-1, mCSF) – all in one product and accepted as one active pharmaceutical ingredient from regulatory perspective.

AUP-16 is topically applied on chronic wounds and covered by wound dressing (e.g. in diabetic foot ulcers, venous leg ulcers and pressure ulcers). In the wound AUP-16 acts as millions of bioreactors producing the therapeutic proteins, which are designed to i) halt chronic inflammation in the wound, ii) induce growth of new blood vessels, and iii) promote granulation tissue formation and skin re-epithelization – all in one product.

AUP-16 is at clinical trial application submission stage in Europe. It is produced and scaled-up at GMP level with low cost-of-goods, has passed GLP safety and toxicity studies, and is planned to enter phase



AUREALIS PHARMA

Hochbergerstrasse 60C

CH-4057 Basel

Switzerland

[www.aurealispharma.com](http://www.aurealispharma.com)

Microkatu 1

FI-70210 Kuopio

Finland

1 clinical trial in 2018. It has passed EU regulatory authority scientific advice and is showing superior efficacy in non-clinical efficacy studies in non-healing diabetic wounds.

#### About Arealis Pharma

Arealis Pharma is a Basel, Switzerland and Kuopio, Finland based privately-held biopharmaceutical company focusing on developing broadly applicable proprietary technology to re-educate the distorted host immune microenvironment in chronic inflammation and cancer to its proper state. Company's technology is based on safe food-grade lactic acid bacteria delivering multiple human therapeutic proteins in target tissue effectively, safely and economically to address the unmet medical need in chronic wounds and cancer.

For more information:

Juha Yrjänheikki, CEO

Arealis Pharma

Tel: +358 45 8433550

Email: [juha\(at\)aurealispharma.com](mailto:juha(at)aurealispharma.com)



AUREALIS PHARMA

Hochbergerstrasse 60C

CH-4057 Basel

Switzerland

[www.aurealispharma.com](http://www.aurealispharma.com)

Microkatu 1

FI-70210 Kuopio

Finland